Replimune (REPL) Exchange Rate Effect (2017 - 2026)
Replimune (REPL) posted Exchange Rate Effect of $50000.0 for Q1 2026, down 95.17% sequentially from $1.0 million in Q4 2025, and down 88.64% YoY from $440000.0 in Q1 2025.
Powered by 
Analysis
Replimune (REPL) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Replimune has reported Exchange Rate Effect for 10 years, with the latest figure at $50000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 88.64% year-over-year to $50000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 253.02% YoY) and the FY2026 annual result came in at $1.1 million, up 253.02% from the prior year.
- Exchange Rate Effect fell to $50000.0 in Q1 2026 per REPL's latest filing, from $1.0 million in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $2.4 million in Q3 2022 and troughed at -$4.5 million in Q1 2023.
- A 5-year average of $84058.8 and a median of $13000.0 in 2023 frame the typical range for Exchange Rate Effect.
- The widest YoY moves for Exchange Rate Effect: up 2591.8% in 2025, down 4517.14% in 2025.
- Over 5 years, Exchange Rate Effect stood at -$8000.0 in 2022, then plunged by 237.5% to -$27000.0 in 2023, then sank by 459.26% to -$151000.0 in 2024, then jumped by 786.09% to $1.0 million in 2025, then sank by 95.17% to $50000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $50000.0, $1.0 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -2.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.84 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -287,000.00 |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 1.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.27 Mn |
| Mar 31, 2026 | 50,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Mar 31, 2025 | 440,000.00 |
| Dec 31, 2024 | -151,000.00 |
| Sep 30, 2024 | 61,000.00 |
| Jun 30, 2024 | -35,000.00 |
| Mar 31, 2024 | -56,000.00 |
| Dec 31, 2023 | -27,000.00 |
| Sep 30, 2023 | -16,000.00 |
| Jun 30, 2023 | 13,000.00 |
| Mar 31, 2023 | -4.45 Mn |
| Dec 31, 2022 | -8,000.00 |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 1.92 Mn |
| Mar 31, 2022 | 197,000.00 |
| Dec 31, 2021 | 105,000.00 |
| Sep 30, 2021 | 304,000.00 |